Clinical Trial Update: Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9 [Phase 3]

View source ↗

Summary

Phase 3 trial update assessing persistence of Tdap vaccine (Boostrix) over 1, 3, 5, and 9 years after initial dose and immunogenicity/safety of a second dose at…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acellular Pertussis
• Diphtheria
• Tetanus

Drugs mentioned

• Boostrix (Diphtheria, Tetanus, and Acellular Pertussis Vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Acellular Pertussis, Tetanus | Phase 3 | Status: COMPLETED | Results posted: 2010-08-11